Date:2/6/2013

d cause actual results to differ include, but are not limited to, the early stage of ZFP Therapeutic development, the lengthy and uncertain regulatory approval process, uncertainties related to the timing of initiation and completion of clinical trials, whether clinical trial results will validate and support the safety and efficacy of ZFP Therapeutics, and the ability to establish strategic partnerships.  Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Sangamo and its partners will be able to develop commercially viable gene-based therapeutics. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in Sangamo's operations and business environments. These risks and uncertainties are described more fully in Sangamo's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q as filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and Sangamo undertakes no duty to update such information except as required under applicable law.SELECTED CONSOLIDATED FINANCIAL DATA(in thousands, except per share data)(unaudited) Three Months Ended Twelve Months Ended December 31,  December 31, 2012201120122011Statement of Operations Data:Revenues:Collaboration agreements

$
8,520$
3,234$  18,186$
,110Research grants

4111,5143,4694,209Total revenues

8,9314,74821,65510,319Operating expenses:Research and development

9,2817,87831,70932,098General and administrative

3,0193,23512,14414,042Total operating expenses

12,30011,11343,85346,140Loss from operations

(3,369)(6,365)(22,198)(35,821)Interest and other income (expense), net

(109)6(66)71Net loss

$
(3,478)$
(6,359)$(22,264)$(35,750)Basic and diluted net loss per common share

$
(0.07)$
(0.12)$<
'/>"/>

SOURCE Sangamo BioSciences, Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Sangamo BioSciences to Webcast Analyst Briefing on Thursday, December 6, 2012
2. Sangamo BioSciences Reports Second Quarter 2012 Financial Results
3. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
4. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
5. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
6. IntelliCell BioSciences Receives Notice of Allowance for its US Patent for "Ultrasonic Cavitation of Adipose Tissue to Produce Stromal Vascular Fraction Regenerative Cells"
7. Regado Biosciences, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York, NY
8. Pressure BioSciences Announces Conversion of All Remaining Series E Convertible Preferred Stock by Ironridge BioPharma
9. Neurocrine Biosciences To Present At Deutsche Banks 2012 dbAccess BioFEST
10. Pressure BioSciences Partners with Constant Systems to Significantly Expand Product Offerings and International Distribution
11. Pressure BioSciences, Inc. to Discuss Third Quarter 2012 Financial Results and Provide Business Update